Crisugabalin Besilate

苯磺酸克利加巴林

Report date: 2026/03/10 20:00:16
NME

Base Information

Drug NameCrisugabalin Besilate
Drug Alias Name思美宁HSK-16149HSK16149
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVoltage-gated calcium channel alpha2/delta subunit 1 blockers
TargetsVoltage-gated calcium channel alpha2/delta subunit 1
Therapy Area/IndicationsDiabetic peripheral neuropathyAnxiety DisordersPain, Postoperative +[13] 
Global Approved IndicationsDiabetic Neuropathies
Approved Indications in ChinaDiabetic Neuropathies
Original Approved Country/TerritoryMainland China
Original Approved Date2024/05/15
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHaisco Pharmaceutical Group Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAnhui Medical UniversityBeijing Friendship Hospital Co LtdLiaoning Haisco Pharmaceutical Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsDiabetic peripheral neuropathyAnxiety DisordersPain, Postoperative +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeN02BF
Related LinksWikipedia